Understanding immune evasion in metastatic non-small cell lung cancer (mNSCLC) with the Tumor Inflammation Signature
|SPEAKER:||Nina Radosevic-Robin, MD, Surgical & Molecular Pathologist, University Clermont Auvergne, INSERM|
Sep 18, 2019
Robust and versatile clinical biomarkers are urgently needed to identify cancer patients who may benefit from immune checkpoint inhibitors (ICI). For translational research, the Tumor Inflammation Signature (TIS) is an 18-gene Research Use Only signature measuring the pathways associated with a suppressed adaptive immune response, which may correlate with ICI clinical benefit (Ayers, J Clin Invest 2017). In this webinar, we will discuss the performance of TIS and additional gene expression signatures contained in the nCounter® PanCancer IO 360™ Gene Expression Panel to assess pathways associated with immune evasion in a study involving retrospectively collected metastatic NSCLC (mNSCLC) tumor samples treated with 2nd+ line nivolumab at two French cancer centers.
The PanCancer IO 360 Panel and accompanying gene signatures, including the TIS, are for Research Use Only. Not for Use in Diagnostic Procedures.